CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Dapagliflozin for treating chronic heart failure with reduced ejection fraction Association of Cardiovascular Disease With Respiratory Disease Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics. Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5)
|<<... 10 11 12 13 14 15 16 >>|

Clinical Trial2021 Jan 26;143(4):310-321.

JOURNAL：Circulation. Article Link

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced

F Zannad, JP Ferreira, SJ Pocock et al. Keywords: empagliflozin; glomerular filtration rate; heart failure; renal insufficiency; chronic

Full Text PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top